SELLAS Life Sciences Group, Inc.’s SLS share price has surged by 21.80%, which has investors questioning if this is right time to sell.

NEW YORK - SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), a biopharmaceutical company with a market capitalization of $81 million engaged in developing cancer therapies, has announced a registered ...

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer ...

Vincerx’s pipeline consists of a next-generation ADC, VIP943, currently in Phase 1; a small molecule drug conjugate, VIP236, which has completed its Phase 1 study; a CDK9 inhibitor, enitociclib, which ...

The Company is also developing SLS009 (formerly GFH009) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared ...

It focuses on the discovery and development of oncology therapeutics. The company’s products include ENITOCICLIB, a CDK9 inhibitor, and several antibody-drug conjugates (ADCs) such as VIP236, VIP943, ...

Aromatase is an enzyme that converts testosterone to estradiol, a type of estrogen. One study found that taking an estrogen blocker called an aromatase inhibitor while on testosterone therapy reduced ...

The inhibition of the BCL-2 family pro-survival proteins, which are frequently overexpressed in B-cell malignancies and pose a fundamental carcinogenic mechanism has been proposed as a promising ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

SELLAS also reported positive data from its Phase 2 trial of SLS009, a selective CDK9 inhibitor, with a median overall survival exceeding 7.7 months. Additionally, the company received FDA Rare ...

Tyrosine (Tyr) phosphorylation of p27 by Abl and Src family kinases reduces p27–CDK2 inhibition and transforms p27 from inhibitor to substrate of cyclin–CDK2 complexes. p27 phosphorylation at ...